Evaluating the Prognostic and Therapeutic Potentials of the Proteasome 26S Subunit, ATPase ( PSMC ) Family of Genes in Lung Adenocarcinoma: A Database Mining Approach

• Published in: Frontiers in genetics Vol. 13; p. 935286
• Main Authors: Ullah, Md Asad, Islam, Nafisa Nawal, Moin, Abu Tayab, Park, Su Hyun, Kim, Bonglee
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.07.2022
• Subjects: biomarker; diagnostic; Genetics; lung cancer; PSMCs; therapeutic; lung cancer; therapeutic; diagnostic; PSMCs; biomarker
• ISSN: 1664-8021; 1664-8021
• DOI: 10.3389/fgene.2022.935286

This study explored the prognostic and therapeutic potentials of multiple Proteasome 26S Subunit, ATPase ( ) family of genes ( ) in lung adenocarcinoma (LUAD) diagnosis and treatment. All the s were found to be differentially expressed (upregulated) at the mRNA and protein levels in LUAD tissues. The promoter and multiple coding regions of s were reported to be differentially and distinctly methylated, which may serve in the methylation-sensitive diagnosis of LUAD patients. Multiple somatic mutations (alteration frequency: 0.6-2%) were observed along the coding regions in LUAD tissues that could assist in the high-throughput screening of LUAD patients. A significant association between the overexpression and LUAD patients' poor overall and relapse-free survival ( < 0.05; HR: >1.3) and individual cancer stages ( < 0.001) was discovered, which justifies s as the ideal targets for LUAD diagnosis. Multiple immune cells and modulators (i.e., CD274 and IDO1) were found to be associated with the expression levels of in LUAD tissues that could aid in formulating -based diagnostic measures and therapeutic interventions for LUAD. Functional enrichment analysis of neighbor genes of s in LUAD tissues revealed different genes (i.e., and ) previously known to be involved in oncogenic processes and metastasis are co-expressed with s, which could also be investigated further. Overall, this study recommends that and their transcriptional and translational products are potential candidates for LUAD diagnostic and therapeutic measure discovery.